Bristol Myers Squibb will team with generative AI company VantAI to find new molecular glues for targeted therapeutic purposes.

百时美施贵宝（Bristol-Myers Squibb）将与generative AI公司万泰（VantAI）合作，寻找用于靶向治疗目的的新分子胶。

The collaboration will utilize New York-based VantAI’s AI platform to craft molecular glues as potential treatments. Under the agreement, VantAI stands to gain up to $674 million in milestone payments from BMS, along with royalties, and the opportunity to expand to additional therapeutic programs.

该合作将利用总部位于纽约的万泰AI平台制作分子胶作为潜在的治疗方法。根据该协议，万泰将从BMS获得高达6.74亿美元的里程碑付款，以及版税，并有机会扩展到其他治疗计划。

This collaboration merges VantAI's advanced AI capabilities with BMS’ expertise in protein degradation, aiming to uncover and develop small molecule therapeutics.

这项合作将万泰的先进人工智能功能与BMS在蛋白质降解方面的专业知识相结合，旨在发现和开发小分子疗法。

VantAI’s technology employs geometric deep learning to glean insights from natural protein interfaces, streamlining the design process for potential therapies.

万泰的技术利用几何深度学习从天然蛋白质界面收集见解，简化潜在疗法的设计过程。

While the full benefits of AI in pharma are still unfolding, companies are cautiously exploring its potential. In 2023, the industry saw a rise in partnerships between AI companies and pharma leaders, with big players like Sanofi, AstraZeneca and Boehringer Ingelheim inking deals.

虽然人工智能在制药领域的全部好处仍在显现，但各公司正在谨慎探索其潜力。2023年，该行业见证了人工智能公司与制药领导者之间合作关系的增长，赛诺菲、阿斯利康和勃林格殷格翰等大公司正在签署协议。